Abstract: AIM:To observe the therapeutic efficacy and mechanism of rosuvastatin combined with benazepril on patients with paroxysmal atrial fibrillation (PAF). METHODS: Seventy patients with PAF were randomized to reagent group and control group. Patients in the reagent group were given amiodarone, rosuvastatin and benazepril, whereas patients in control group were given amiodarone alone. Therapeutic efficacy, serum level of C-reactive protein (CRP) and left atrial diameter (LAD) were observed. RESULTS: After 6 months’ follow-up, PAF times and AF duration were significantly decreased and the total effective rate was elevated in the reagent group compared with those in the control group (P<0.05). Serum level of CRP and the size of the LAD in the reagent group were significantly lower than those in the control group (P<0.05). CONCLUSION: Rosuvastatin combined with benazepril effectively inhibits the occurrence of PAF and the mechanism is probably associated with the effect of inflammatory reaction reduction and myocardium reconstitution inhibition.